Celgene To Pay $280M To End Off-Label Cancer Drug FCA Suit
Celgene Corp. has agreed to shell out $280 million to end a False Claims Act suit launched in California by a whistleblower who accused the drug company of promoting off-label uses...To view the full article, register now.
Already a subscriber? Click here to view full article